What AbbVie’s $63 Billion Deal to Buy Allergan Says About the Drug Industry

AbbVie reported on Tuesday that it will purchase Allergan in an arrangement esteemed at about $63 billion, a 45% premium on Allergan’s latest shutting stock cost. The proposed M&A will be one of the biggest medicinal services mergers of the year and unite a portfolio Continue Reading